Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status

Hepatocellular carcinoma (HCC) is one of the most deadly and frequent cancers worldwide, although great advancement in the treatment of this malignancy have been made within the past few decades. It continues to be a major health issue due to an increasing incidence and a poor prognosis. The majorit...

Full description

Bibliographic Details
Main Authors: Kun Qian, Feng Zhang, Stephen K. Allison, Chuansheng Zheng, Xiaoming Yang
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2021-02-01
Series:Journal of Interventional Medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2096360220300740
id doaj-24252b7b56644f83bf489aaffd40581e
record_format Article
spelling doaj-24252b7b56644f83bf489aaffd40581e2021-02-13T04:24:04ZengKeAi Communications Co., Ltd.Journal of Interventional Medicine2096-36022021-02-014117Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current statusKun Qian0Feng Zhang1Stephen K. Allison2Chuansheng Zheng3Xiaoming Yang4Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China; Department of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington School of Medicine, Seattle, WA, 98109, USADepartment of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington School of Medicine, Seattle, WA, 98109, USADivision of Interventional Radiology, Department of Radiology, University of Washington School of Medicine, Seattle, WA, 98109, USADepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, ChinaDepartment of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington School of Medicine, Seattle, WA, 98109, USA; Division of Interventional Radiology, Department of Radiology, University of Washington School of Medicine, Seattle, WA, 98109, USA; Corresponding author. Department of Radiology, Image-Guided Biomolecular Intervention Research, University of Washington, School of Medicine, 850 Republican Street, Seattle, WA, 98109, USA.Hepatocellular carcinoma (HCC) is one of the most deadly and frequent cancers worldwide, although great advancement in the treatment of this malignancy have been made within the past few decades. It continues to be a major health issue due to an increasing incidence and a poor prognosis. The majority of patients have their HCC diagnosed at an intermediate or advanced stage in theUSA or China. Curative therapy such as surgical resection or liver transplantation is not considered anoption of treatment at these stages.Transarterial chemoembolization (TACE), the most widely used locoregional therapeutic approach, used to be the mainstay of treatment for cases with unresectable cancer entities. However, for those patients with hypovascular tumors or impaired liver function reserve, TACE is a suboptimal treatment option. For example, embolization does not result in complete coverage of a hypovascular tumor, and may rather promotes postoperative tumor recurrence, or leave residual tumor, in these TACE-resistance patients. In addition, TACE carries a higher risk of hepatic decompensation in patients with poor liver function or reserve.Non-vascular interventional locoregional therapies for HCC include radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), laser-induced thermotherapy (LITT), cryosurgical ablation (CSA), irreversible Electroporation (IRE), percutaneous ethanol injection (PEI), and brachytherapy. Recent advancements in these techniques have significantly improved the treatment efficacy of HCC and expanded the population of patients who qualify for treatment. This review embraces the current status of imaging-guided locoregional non-intravascular interventional treatments for HCCs, with a primary focus on the clinical evaluation and assessment of the efficacy of combined therapies using these interventional techniques.http://www.sciencedirect.com/science/article/pii/S2096360220300740
collection DOAJ
language English
format Article
sources DOAJ
author Kun Qian
Feng Zhang
Stephen K. Allison
Chuansheng Zheng
Xiaoming Yang
spellingShingle Kun Qian
Feng Zhang
Stephen K. Allison
Chuansheng Zheng
Xiaoming Yang
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
Journal of Interventional Medicine
author_facet Kun Qian
Feng Zhang
Stephen K. Allison
Chuansheng Zheng
Xiaoming Yang
author_sort Kun Qian
title Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
title_short Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
title_full Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
title_fullStr Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
title_full_unstemmed Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status
title_sort image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: current status
publisher KeAi Communications Co., Ltd.
series Journal of Interventional Medicine
issn 2096-3602
publishDate 2021-02-01
description Hepatocellular carcinoma (HCC) is one of the most deadly and frequent cancers worldwide, although great advancement in the treatment of this malignancy have been made within the past few decades. It continues to be a major health issue due to an increasing incidence and a poor prognosis. The majority of patients have their HCC diagnosed at an intermediate or advanced stage in theUSA or China. Curative therapy such as surgical resection or liver transplantation is not considered anoption of treatment at these stages.Transarterial chemoembolization (TACE), the most widely used locoregional therapeutic approach, used to be the mainstay of treatment for cases with unresectable cancer entities. However, for those patients with hypovascular tumors or impaired liver function reserve, TACE is a suboptimal treatment option. For example, embolization does not result in complete coverage of a hypovascular tumor, and may rather promotes postoperative tumor recurrence, or leave residual tumor, in these TACE-resistance patients. In addition, TACE carries a higher risk of hepatic decompensation in patients with poor liver function or reserve.Non-vascular interventional locoregional therapies for HCC include radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), laser-induced thermotherapy (LITT), cryosurgical ablation (CSA), irreversible Electroporation (IRE), percutaneous ethanol injection (PEI), and brachytherapy. Recent advancements in these techniques have significantly improved the treatment efficacy of HCC and expanded the population of patients who qualify for treatment. This review embraces the current status of imaging-guided locoregional non-intravascular interventional treatments for HCCs, with a primary focus on the clinical evaluation and assessment of the efficacy of combined therapies using these interventional techniques.
url http://www.sciencedirect.com/science/article/pii/S2096360220300740
work_keys_str_mv AT kunqian imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus
AT fengzhang imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus
AT stephenkallison imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus
AT chuanshengzheng imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus
AT xiaomingyang imageguidedlocoregionalnonintravascularinterventionaltreatmentsforhepatocellularcarcinomacurrentstatus
_version_ 1724271939031138304